On February 2, 2023 Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, reported the company’s participation in the following investor conferences (Press release, Arcellx, FEB 2, 2023, View Source [SID1234626797]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim Oncology Conference 2023
Fireside chat on Thursday, February 9, 2023, at 11:20 a.m. ET

SVB Securities Global Biopharma Conference (Virtual)
Fireside chat on Thursday, February 16, 2023, at 3:00 p.m. ET
A live webcast of these discussions will be accessible from Arcellx’s website at www.arcellx.com in the Investors section. A replay of the webcasts will be archived and available for 30 days following the event.